Targeted therapy in advanced desmoid tumors: Current perspectives

[1]Biermann JS: Desmoid tumors. Curr Treat Options Oncol 2000; 1:262–266.BiermannJSDesmoid tumorsCurr Treat Options Oncol2000126226610.1007/s11864-000-0038-512057169Search in Google Scholar

[2]Dufresne A, Paturel M, Alberti L, et al. Prediction of desmoid tumor progression using miRNA expression profiling. Cancer Sci 2015; 106: 650– 655.DufresneAPaturelMAlbertiLet alPrediction of desmoid tumor progression using miRNA expression profilingCancer Sci2015106650–65510.1111/cas.12640445216825707497Search in Google Scholar

[3]Wu C, Amini-Nik S, Nadesan P, et al. Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells. Cancer Res. 2010; 70: 7690–8WuCAmini-NikSNadesanPet alAggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cellsCancer Res2010707690810.1158/0008-5472.CAN-10-165620841474Search in Google Scholar

[4]Dalen BP, Bergh PM, Gunterberg BU. Desmoid tumors: a clinical review of 30 patients with more than 20 years’ follow-up. Acta Orthop. Scand. 2003, 74, 455–459.DalenBPBerghPMGunterbergBUDesmoid tumors: a clinical review of 30 patients with more than 20 years’ follow-upActa Orthop. Scand20037445545910.1080/0001647031001778514521298Search in Google Scholar

[5]Malik F, Korkaya H, Clouthier SG, et al. Breast cancer heterogeneity: need to review current treatment strategies. Curr Breast Cancer Rep 2012; 4: 225–31.MalikFKorkayaHClouthierSGet alBreast cancer heterogeneity: need to review current treatment strategiesCurr Breast Cancer Rep201242253110.1007/s12609-012-0093-5Search in Google Scholar

[6]Rothschild SI, Gautschi O. Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data. Clinical Investigation 2012; 2: 387–96.RothschildSIGautschiOSrc tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical dataClinical Investigation201223879610.4155/cli.12.27Search in Google Scholar

[7]Escobar C, Munker R, Thomas JO, et al. Update on desmoid tumors. Ann Oncol 2012; 23: 562.EscobarCMunkerRThomasJOet alUpdate on desmoid tumorsAnn Oncol20122356210.1093/annonc/mdr38621859899Search in Google Scholar

[8]Schiessling S, Kihm M, Ganschow P, et al. Desmoid tumour biology in patients with familial adenomatous polyposis coli. Br J Surg 2013; 100: 694–703.SchiesslingSKihmMGanschowPet alDesmoid tumour biology in patients with familial adenomatous polyposis coliBr J Surg201310069470310.1002/bjs.905323334997Search in Google Scholar

[9]Lazar AJ, Hajibashi S, Lev D. Desmoid tumor: from surgical extirpation to molecular dissection. Curr Opin Oncol 2009; 21: 352.LazarAJHajibashiSLevDDesmoid tumor: from surgical extirpation to molecular dissectionCurr Opin Oncol20092135210.1097/CCO.0b013e32832c950219436199Search in Google Scholar

[10]Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007; 61: 153.NieuwenhuisMHVasenHFCorrelations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literatureCrit Rev Oncol Hematol20076115310.1016/j.critrevonc.2006.07.00417064931Search in Google Scholar

[11]Sinha A, Tekkis PP, Gibbons DC, et al. Risk factors predicting desmoids occurrence in patients with familial adenomatous polyposis: a meta-analysis. Colorectal Dis 2011; 13: 1222–9.SinhaATekkisPPGibbonsDCet alRisk factors predicting desmoids occurrence in patients with familial adenomatous polyposis: a meta-analysisColorectal Dis2011131222910.1111/j.1463-1318.2010.02345.x20528895Search in Google Scholar

[12]Wallis YL, Morton DG, Mc Keown CM, et al. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. J Med Genet 1999; 36: 14–20.WallisYLMortonDGMcKeown CMet alMolecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predispositionJ Med Genet1999361420Search in Google Scholar

[13]Bertario L, Russo A, Sala P, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21: 1698.BertarioLRussoASalaPet alMultiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposisJ Clin Oncol200321169810.1200/JCO.2003.09.11812721244Search in Google Scholar

[14]Church J, Xhaja X, LaGuardia L, et al. Desmoids and genotype in familial adenomatous polyposis. Dis Colon Rectum. 2015; 58: 444–8.ChurchJXhajaXLaGuardiaLet alDesmoids and genotype in familial adenomatous polyposisDis Colon Rectum201558444810.1097/DCR.000000000000031625751801Search in Google Scholar

[15]Narayan S and Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer. 2003; 2: 41.NarayanSandRoyDRole of APC and DNA mismatch repair genes in the development of colorectal cancersMol Cancer200324110.1186/1476-4598-2-4131735514672538Search in Google Scholar

[16]Dômont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. Br J Cancer 2010; 102: 1032–1036.DômontJSalasSLacroixLet alHigh frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease managementBr J Cancer20101021032103610.1038/sj.bjc.6605557284402420197769Search in Google Scholar

[17]Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoids tumors. Am J Pathol 2008; 173: 1518–1527.LazarAJTuvinDHajibashiSet alSpecific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoids tumorsAm J Pathol20081731518152710.2353/ajpath.2008.080475257014118832571Search in Google Scholar

[18]Colombo C, Miceli R, Lazar AJ, Perrone F, et al. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoids tumor recurrence: An independent, multicenter validation study. Cancer 2013; 119: 3696–3702.ColomboCMiceliRLazarAJPerroneFet alCTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoids tumor recurrence: An independent, multicenter validation studyCancer20131193696370210.1002/cncr.2827123913621Search in Google Scholar

[19]Mullen JT, DeLaney TF, Rosenberg AE, et al. beta-catenin mutation status and outcomes in sporadic desmoids tumors. Oncologist 2013; 18: 1043– 1049.MullenJTDeLaneyTFRosenbergAEet albeta-catenin mutation status and outcomes in sporadic desmoids tumorsOncologist2013181043–104910.1634/theoncologist.2012-0449378063623960186Search in Google Scholar

[20]Cho NL, Carothers AM, Rizvi H, et al. Immunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumors. J Surg Res. 2012; 173: 320–6.ChoNLCarothersAMRizviHet alImmunohistochemical and molecular analysis of tyrosine kinase activity in desmoid tumorsJ Surg Res2012173320610.1016/j.jss.2010.10.03721195420Search in Google Scholar

[21]Santos GA, Cunha IW, Rocha RM, et al. Evaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment options. Biosci Trends. 2010; 4: 25–30.SantosGACunhaIWRochaRMet alEvaluation of estrogen receptor alpha, estrogen receptor beta, progesterone receptor, and cKIT expression in desmoids tumors and their role in determining treatment optionsBiosci Trends201042530Search in Google Scholar

[22]Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer 2010; 49: 560–568.SalasSChibonFNoguchiTet alMolecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumorsGenes Chromosomes Cancer20104956056810.1002/gcc.2076620232483Search in Google Scholar

[23]Gebert C, Hardes J, Kersting C, et al. Expression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosis. Histopathology 2007; 50: 491–497.GebertCHardesJKerstingCet alExpression of beta-catenin and p53 are prognostic factors in deep aggressive fibromatosisHistopathology20075049149710.1111/j.1365-2559.2007.02619.x17448025Search in Google Scholar

[24]Bacac M, Migliavacca E, Stehle JC, et al. A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol. 2006; 208: 543–53.BacacMMigliavaccaEStehleJCet alA gene expression signature that distinguishes desmoid tumours from nodular fasciitisJ Pathol20062085435310.1002/path.191516440290Search in Google Scholar

[25]Urakawa H, Nishida Y, Naruse T, et al. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: A pilot study. Clin Orthop Relat Res 2009: 467: 2932–2938.UrakawaHNishidaYNaruseTet alCyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: A pilot studyClin Orthop Relat Res20094672932293810.1007/s11999-009-0814-x275897019326179Search in Google Scholar

[26]Hong H, Nadesan P, Poon R, et al. Testosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumor). Br J Cancer 2011; 104: 1452–1458.HongHNadesanPPoonRet alTestosterone regulates cell proliferation in aggressive fibromatosis (desmoid tumor)Br J Cancer20111041452145810.1038/bjc.2011.107310192621468052Search in Google Scholar

[27]de Camargo VP, Keohan ML, D’Adamo DR, et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer. 2010; 116: 2258–2265.deCamargo VPKeohanMLD’AdamoDRet alClinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)Cancer20101162258226510.1002/cncr.25089292510620187095Search in Google Scholar

[28]Mace J, Sybil Biermann J, Sondak V, et al., “Response of extraabdominal desmoid tumors to therapy with imatinib mesylate,” Cancer 2002; 95: 2373–2379.MaceJSybilBiermann JSondakVet al“Response of extraabdominal desmoid tumors to therapy with imatinib mesylate” Cancer2002952373237910.1002/cncr.1102912436445Search in Google Scholar

[29]Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006; 24: 1195– 1203.HeinrichMCMcArthurGADemetriGDet alClinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)J Clin Oncol2006241195–120310.1200/JCO.2005.04.071716505440Search in Google Scholar

[30]Chugh R, Wathen JK, Patel SR, et al. Sarcoma Alliance for Research through Collaboration (SARC). Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 2010; 16: 4884–4891.ChughRWathenJKPatelSRet alSarcoma Alliance for Research through Collaboration (SARC)Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res2010164884489110.1158/1078-0432.CCR-10-117720724445Search in Google Scholar

[31]Penel N, Le Cesne A, Bui BN, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol 2011, 22: 452–457.PenelNLe CesneABuiBNet alImatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-upAnn Oncol20112245245710.1093/annonc/mdq34120622000Search in Google Scholar

[32]Gounder MM, Lefkowitz RA, Keohan ML, et al. Activity of sorafenib against desmoids tumor/deep fibromatosis. Clin Cancer Res 2011; 17: 4082– 4090.GounderMMLefkowitzRAKeohanMLet alActivity of sorafenib against desmoids tumor/deep fibromatosisClin Cancer Res2011174082–409010.1158/1078-0432.CCR-10-3322315298121447727Search in Google Scholar

[33]Jo JC, Hong YS, Kim KP, et al. A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis. Invest New Drugs. 2014; 32: 369–76.JoJCHongYSKimKPet alA prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosisInvest New Drugs2014323697610.1007/s10637-013-0059-024425345Search in Google Scholar

[34]Scheer L, Lodi M, Molière S, Kurtz JE, Mathelin C.Medical treatment of mammary desmoid-type fibromatosis: which benefit? World J Surg Oncol. 2017: 18; 15: 86.ScheerLLodiMMolièreSKurtzJEMathelinCMedical treatment of mammary desmoid-type fibromatosis: which benefit?World J Surg Oncol201718158610.1186/s12957-017-1148-x539585328420393Search in Google Scholar

[35]Skubitz KM, Manivel JC, Clohisy DR, Frolich JW.Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors. Cancer Chemother Pharmacol. 2009; 64: 635–40.SkubitzKMManivelJCClohisyDRFrolichJWResponse of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitorsCancer Chemother Pharmacol2009646354010.1007/s00280-009-1010-019404642Search in Google Scholar

[36]Martin-Liberal J, Benson C, McCarty H, et al. Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res. 2013; 26; 31: 13.Martin-LiberalJBensonCMcCartyHet alPazopanib is an active treatment in desmoid tumour/aggressive fibromatosisClin Sarcoma Res201326311310.1186/2045-3329-3-13417648624279994Search in Google Scholar

[37]Toulmonde M, Bellera C, Mathoulin-Pelissier S, et al.DESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Group. ournal of Clinical Oncology 2018; 36: 11501– 11501.ToulmondeMBelleraCMathoulin-PelissierSet alDESMOPAZ pazopanib (PZ) versus IV methotrexate/vinblastine (MV) in adult patients with progressive desmoid tumors (DT) a randomized phase II study from the French Sarcoma Groupournal of Clinical Oncology20183611501–1150110.1200/JCO.2018.36.15_suppl.11501Search in Google Scholar

[38]Kummar S, O’Sullivan Coyne G, Do KT, et al. Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults with Desmoid Tumors (Aggressive Fibromatosis). J Clin Oncol. 2017 10; 35: 1561–1569.KummarSO’SullivanCoyne GDoKTet alClinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults with Desmoid Tumors (Aggressive Fibromatosis)J Clin Oncol201710351561156910.1200/JCO.2016.71.1994545570628350521Search in Google Scholar